PharmaShots Weekly Snapshot (April 27 -May 01, 2020)

WuXi Biologics and Aravive Collaborate to Develop Novel High-Affinity Bispecific Antibodies for Cancer and Fibrosis

Published: Apr 30, 2020 | Tags: WuXi Biologics, Aravive, Collaborate, Develop, Novel, High-Affinity Bispecific Antibodies, Cancer,  Fibrosis

 Novartis’ Enerzair Breezhaler (QVM149, IND/GLY/MF) Receives CHMP’s Recommendation for Approval as a Treatment for Uncontrolled Asthma

Published: May 01, 2020 | Tags: Novartis, Enerzair, Breezhaler, QVM149, IND/GLY/MF, Receives, CHMP, Recommendation, Approval, Treatment, Uncontrolled Asthma

 Moderna Signs a Ten-Year Worldwide Agreement with Lonza to Manufacture mRNA-1273 Against COVID-19

Published: May 01, 2020 | Tags: Moderna, Signs, Ten-Year, Worldwide, Agreement, Lonza, Manufacture, mRNA-1273, Against, COVID-19

Pfizer Signs a Development and Commercialization Agreement with Valneva for Lyme Disease Vaccine

Published: Apr 30, 2020 | Tags: Pfizer, Signs, Development, Commercialization, Agreement, Valneva, Lyme Disease, Vaccine Candidate

 MSD Signs a Two-Year Research Agreement with Almac to Discover DUB Therapeutic Targets for Neurodegenerative Diseases

Published: Apr 29, 2020 | Tags: MSD, Signs, Two-Year, Research Agreement, Almac, Discover, DUB Therapeutic Targets,  Neurodegenerative Diseases

Bergenbio’s Bemcentinib Selected to be Fast-Tracked Under UK’s ACCORD Program Targeting COVID-19

Published: Apr 23, 2020 | Tags: Bergenbio, Bemcentinib, Fast-Tracked, UK, ACCORD Program, Targeting, COVID-19

 GSK’s Zejula (niraparib) Receives the US FDA’s Approval as 1L Monotherapy Maintenance Treatment for Women with Advanced Ovarian Cancer Regardless of Biomarker Status

Published: Apr 29, 2020 | Tags: GSK, Zejula, niraparib, Receives, US, FDA, Approval, 1L, Monotherapy, Maintenance Treatment, Women, Advanced Ovarian Cancer, Biomarker Status

AstraZeneca Signs a Worldwide Development and Distribution Agreement with Oxford University for Vaccine Against COVID-19

Published: Apr 30, 2020 | Tags: AstraZeneca, Signs, Worldwide, Development, Distribution, Agreement, Oxford University, Vaccine, Against, COVID-19

Gilead Reports Results of Remdesivir in P-III SIMPLE Studies for Patients with Severe COVID-19

Published: Apr 29, 2020 | Tags: Gilead, Reports, Results, Remdesivir, P-III, SIMPLE Studies, Patients, Severe COVID-19

Johnson & Johnson Signs a Manufacturing Agreement with the Catalent to Bolster the Capacity of COVID-19 Vaccine in the US

Published: Apr 29, 2020 | Tags: Johnson & Johnson, Manufacturing Agreement, Catalent, Bolster, Capacity, COVID-19 Vaccine, US

Merck’s Keytruda (pembrolizumab) Receives the US FDA’s Approval for Additional Recommended Dose of 400 mg Every Six Weeks for All Approved Indications

Published: Apr 29, 2020 | Tags: Merck, Keytruda, pembrolizumab, Receives, US, FDA, Approval, Additional, Recommended Dose, 400 mg, Every Six Weeks, All Approved Indications

Novartis Plans to Commence P-III Clinical Study Evaluating Canakinumab for Patients with COVID-19 Pneumonia

Published: Apr 28, 2020 | Tags: Novartis, Plans, Commence, P-III, Clinical Study, Evaluating, Canakinumab, Patients, COVID-19 Pneumonia

Astellas Signs a Three-Year Research Alliance with Harvard University Across Multiple Therapeutic Areas

Published: Apr 29, 2020 | Tags: Astellas, Signs, Three Years, Research Alliance, Harvard University, Multiple Therapeutics Areas

BioNTech and Pfizer Complete Dosing of BNT162 in First Cohort of P-I/II Study in Germany

Published:  Apr 22, 2020 | Tags: BioNTech, Pfizer, Completes, Dosing, First Cohort, P-I/II, Study, Evaluating, BNT162, Germany

Novartis’ Cosentyx (secukinumab) Receives EC’s Approval for Axial Spondyloarthritis Spectrum Marking its Fourth Indication in EU

Published: Apr 22, 2020 | Tags: Novartis, Cosentyx ,secukinumab, Receives, EC, Approval, Axial Spondyloarthritis Spectrum, Marking, Fourth Indication, EU

Sarepta Signs a Research Agreement with the US Department of Defense to Identify Antisense Oligonucleotides Against COVID-19

Published: Apr 28, 2020 | Tags: Sarepta, Signs, Research Agreement, US Department of Defense, Identify, Antisense Oligonucleotides, Against, COVID-19

Biocon and Mylan Launch Fulphila (biosimilar, pegfilgrastim) in Canada

Published: Apr 28, 2020 | Tags: Biocon, Mylan, Launch, Fulphila, biosimilar, pegfilgrastim, Canada

Moderna to Initiate P-II Study of mRNA-1273 Against Novel COVID-19

Published: Apr 27, 2020 | Tags: Moderna, Initiate, P-II, Study, mRNA-1273, Against, COVID-19

Abbott’s Freestyle Libre System Receives Health Canada Authorization Under Interim Order for Hospitalized Patients During COVID-19

Published: Apr 21, 2020 | Tags: Abbott, Freestyle Libre System, Receives, Health Canada Authorization, Under Interim Order, Hospitalized Patients, COVID-19

Takeda’s Mobocertinib (TAK-788) Receives the US FDA’s Breakthrough Therapy Designation for NSCLC Patients with EGFR Exon 20 Insertion Mutations

Published:  Apr 27, 2020 | Tags:  Takeda, Mobocertinib, TAK-788, Receives, US, FDA, Breakthrough Therapy Designation, NSCLC, Patients, EGFR Exon 20 Insertion Mutations

CEPI Collaborates with Clover to Support the Development of Vaccine Against COVID-19 in Australia

Published: Apr 27, 2020 | Tags: CEPI, Collaborates, Clover, Support, Development of Vaccine, COVID-19, Australia

Roche and PTC Therapeutics Report Results of Risdiplam in FIREFISH Part 2 Study for Infants with Type 1 Spinal Muscular Atrophy

Published: Apr 28, 2020 | Tags: Roche, PTC Therapeutics, Report, Results, Risdiplam, FIREFISH Part 2, Study, Infants, Type 1 Spinal Muscular Atrophy

Merck Collaborates with ISB to Evaluate the Mechanism of COVID-19 and to Identify Potential Prognostic Biomarkers

Published: Apr 27, 2020 | Tags: Merck, Collaborates, ISB, Evaluate, Mechanism of COVID-19, Identify, Potential, Prognostic Biomarkers

Capital Health Launches Antibody Testing Initiative for COVID-19

Published: Apr 27, 2020 | Tags: Capital Health, Launches, Antibody Testing Initiative, COVID-19

Regeneron and Sanofi Provide Update of P-II/III Adaptive-Designed Trial of Kevzara in Hospitalized Patients with COVID-19 in the US

Published: Apr 27, 2020 | Tags: Otsuka, Signs, Development, Commercialization, Agreement, Esperion, Nexletol, bempedoic acid, Nexlizet, bempedoic acid and ezetimibe, Japan

Chugai Reports Results of P-III SAkuraStar Study of Satralizumab for Neuromyelitis Optica Spectrum Disorder

Published: Apr 24, 2020 | Tags: Chugai, Reports, Results, SAkuraStar, Satralizumab, NOSD

Janssen Reports Submission of Two sBLA to the US FDA for SIMPONI ARIA (golimumab) to Treat Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis

Published: Apr 24, 2020 | Tags: Janssen, sBLA, US FDA, SIMPONI ARIA, Polyarticular Juvenile Idiopathic Arthritis, Juvenile Psoriatic Arthritis

Santhera Signs a Clinical Trial Agreement with Cold Spring Harbor Laboratory to Evaluate Lonodelestat (POL6014) Against Acute Respiratory Distress Syndrome Associated with COVID-19

Published: Apr 27, 2020 | Tags: Santhera, Signs, Clinical Trial Agreement, Cold Spring Harbor Laboratory,  Evaluate, Lonodelestat, (POL6014), Against, Acute Respiratory Distress Syndrome Associated, COVID-19

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post